Clinical trial
Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed…
NCT00071396 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00071396 |
|---|---|
| Title | Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders |
| Official title | Continuous Infusion Followed by Subcutaneous Injection of Campath-1H Plus Rituximab in the Treatment of CD52- and CD20-Positive Refractory or Relapsed Chronic Lymphoid Disorders |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Campath-1H, Rituximab |
| Enrollment | 48 |
| Start date | Oct 1, 2002 |
| Primary completion | Sep 1, 2006 |
| Completion | Aug 1, 2007 |
| First posted | Oct 22, 2003 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: